Core Viewpoint - Sanofi Pharmaceutical (01530) saw a significant stock increase, rising over 7% in early trading and currently up 5.25% at HKD 30.88, with a trading volume of HKD 401 million [1] Group 1: Company Developments - Mand International has submitted an application for an independent listing on the Hong Kong Stock Exchange [1] - Mand International is recognized as a leading professional consumer pharmaceutical company in China, focusing on comprehensive and long-term solutions for skin health and weight management [1] - The company has established a leadership position in the hair health sector within the broader skin health industry [1] Group 2: Corporate Actions - Sanofi Pharmaceutical announced plans to spin off its subsidiary, Mand International, for independent listing on the Hong Kong Stock Exchange [1] - Following the spin-off, Sanofi Pharmaceutical will not retain any equity interest in Mand International, which will operate independently [1]

Group 1 - Sanofi Pharmaceutical (01530) saw a morning increase of over 7%, and as of the report, it rose by 5.25% to HKD 30.88, with a trading volume of HKD 401 million [1] - According to the Hong Kong Stock Exchange on November 20, Mandi International has submitted an application for a mainboard listing. The prospectus indicates that Mandi International is a leading professional consumer pharmaceutical company in China, focused on developing and providing comprehensive and long-term solutions for skin health and weight management [1] - Sanofi Pharmaceutical announced its plan to spin off its subsidiary Mandi International for independent listing on the Hong Kong Stock Exchange. After the spin-off, Sanofi will not retain any equity in Mandi International, which will operate independently [1]